The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 27)
Research Grant, 2014
Some forms of familial Parkinson's disease (PD) are due to mutations in the genes that code for the proteins PINK1, DJ-1 and parkin. These proteins have specific roles in the proper regulation of mitochondria, which are responsible for the majority of cellular energy production (ATP) in the cell. By studying pre-clinical models that have dysfunction in these PD genes, we will c...
Researchers: Howard Steven Fox, MD, PhD
Research Grant, 2014
Mutations in the DJ-1 gene cause an early-onset form of Parkinson's disease (PD). The DJ-1 protein is an attractive biomarker for sporadic PD, as well, since it is readily modified by oxidative stress, one of the hypothesized mechanisms of PD pathogenesis. The overall goal of this project is to develop a specific and sensitive assay for oxidized DJ-1 that can be ...
Researchers: Un Jung Kang, MD
Rapid Response Innovation Awards, 2013
Mutations in the DJ-1 gene have been associated with Parkinson's disease onset. This project will determine the 3D structure of the DJ-1 protein in complex with novel drug-like compounds. These compounds were identified by a unique DJ-1 binding screen and are active in protecting from oxidative stress in dopaminergic neurons. The insights from the 3D structure of t...
Biosample and Tissue Resource, 2013
The objective of this study is to explore the role of glycans (sugars attached to proteins) in the development and progression of Parkinson's disease (PD). Glycans play a key role in many important cellular processes, including signaling pathways and immune response, but have not been widely studied due to technical limitations. This study will leverage pharmaceuti...
Research Grant, 2012
We have developed antibodies against an oxidized form of DJ-1 using complementary approaches to be able to use them as a biomarker in PD. A common problem in biomarker studies is that different laboratories often have different results using the same principles. We will work collaboratively to validate the assay tools by sharing our antibodies and testing them ag...